Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trialResearch in context

Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trialResearch in context

Summary: Background: The phase 2 ASUNCTIS study assessed the efficacy and safety of asunercept, a fully human CD95 (Fas) ligand-binding protein, in hospitalised patients with moderate-to-severe coronavirus disease (COVID-19) to assess the clinical benefit of CD95 ligand inhibition in this viral dis...

Full description

Bibliographic Details
Main Authors: Maria Pilar Ruiz Seco, José Ramón Paño Pardo, Christian Schoergenhofer, Christiane Dings, Thorsten Lehr, Felix Herth, Andriy Krendyukov, Carola Straub, Martin Kappler, Bernd Jilma, Harald Fricke, Julian Pardo, Diego de Miguel, Meinolf Thiemann, Michael Bergmann, Henning Walczak, Thomas Hoeger
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:EClinicalMedicine
Subjects:
Asunercept
CD95L (FasL)
COVID-19
Phase 2 clinical trial
Lymphocytopenia
Apoptosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024004589

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024004589

Similar Items